Resources from the same session
57MO - Impact of nirogacestat (niro) on patient-reported outcomes (PROs) in adults with desmoid tumor with a best overall response (BOR) of stable disease (SD): Post hoc analysis from the DeFi study
Presenter: Silvia Stacchiotti
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
58MO - Evaluation of three pexidartinib doses in a global phase IV clinical study of patients with tenosynovial giant cell tumor (TGCT) who chose to continue treatment
Presenter: Silvia Stacchiotti
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
59MO - COTESARC – A multicentre, phase I-II clinical trial evaluating the combination of MEK and PDL-1 inhibitors in patients (pts) with advanced soft tissue sarcoma (STS): Results from complex (CG) and simple genomic (SG) STS cohorts
Presenter: Armelle Dufresne
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
Invited Discussant abstracts 57MO, 58MO and 59MO
Presenter: George Demetri
Session: Mini Oral session
Resources:
Slides
Webcast
60MO - Theranostics in soft tissue sarcoma using a vascular disruption approach: Preliminary results of a proof-of-concept pilot study
Presenter: Antonia Digklia
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
14MO - Safety of cytoreductive surgery with hyperthermic intraperitoneal gemcitabine and systemic dacarbazine for recurrent uterine leiomyosarcoma: Preliminary results of a phase II trial
Presenter: Beatrice Sun
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
61MO - Phase Ia/Ib study of the MDM2-p53 antagonist brigimadlin (BI 907828) in advanced solid tumours: Overall safety, and efficacy in patients (pts) with well-differentiated liposarcoma (WDLPS)
Presenter: Peter Reichardt
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast